Coherus Oncology

Coherus Oncology CHRS Stock

$0.37   -4.469132%
Add to favorites
Market Cap
$57.15M
LOW - HIGH [24H]
$0.36 - $0.41
VOLUME [24H]
$2.52M
P/E Ratio
0
Earnings per share
-$1.12
ISIN
US19249H1032
Price   Prediction

Coherus Oncology Price Chart

Sorry, that's all we've gotfor now...

Coherus Oncology (CHRS) stock price today is 0.37 USD on Tech Market Middle (-4.47% on the day). Updated .

Coherus Oncology CHRS Financial and Trading Overview

Coherus Oncology stock price 0.37 USD
Previous Close 0.41 USD
Open 0.4 USD
Bid 1.51 USD x 300
Ask 1.9 USD x 200
Day's Range 0.37 - 0.41 USD
52 Week Range 0.37 - 2.62 USD
Volume 3.98M USD
Avg. Volume 1.73M USD
Market Cap 59.82M USD
Beta (5Y Monthly) 1.054
PE Ratio (TTM) N/A
EPS (TTM) -1.12 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 7.25 USD

CHRS Valuation Measures

Enterprise Value 45.74M USD
Trailing P/E N/A
Forward P/E -0.62435484
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 1.1152663
Price/Book (mrq) 2.3748467
Enterprise Value/Revenue 0.853
Enterprise Value/EBITDA -0.322

Trading Information

Coherus Oncology Stock Price History

Beta (5Y Monthly) 1.054
52-Week Change -62.72%
S&P500 52-Week Change 12.00%
52 Week High 2.62 USD
52 Week Low 0.37 USD
50-Day Moving Average 1.01 USD
200-Day Moving Average 1.44 USD

CHRS Share Statistics

Avg. Volume (3 month) 1.73M USD
Avg. Daily Volume (10-Days) 3.34M USD
Shares Outstanding 154.54M
Float 147.93M
Short Ratio 8.04
% Held by Insiders 19.11%
% Held by Institutions 34.86%
Shares Short 12.71M
Short % of Float 8.48%
Short % of Shares Outstanding 8.22%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -253.42%
Operating Margin (ttm) -271.092%
Gross Margin 69.81%
EBITDA Margin -264.58%

Management Effectiveness

Return on Assets (ttm) -26.43%
Return on Equity (ttm) -275.17%

Income Statement

Revenue (ttm) 53.64M USD
Revenue Per Share (ttm) 0.38 USD
Quarterly Revenue Growth (yoy) 23.40%
Gross Profit (ttm) 37.45M USD
EBITDA -141919008 USD
Net Income Avi to Common (ttm) -155504000 USD
Diluted EPS (ttm) -1.12
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 83.63M USD
Total Cash Per Share (mrq) 0.54 USD
Total Debt (mrq) 69.55M USD
Total Debt/Equity (mrq) 275.45 USD
Current Ratio (mrq) 1.509
Book Value Per Share (mrq) 0.163

Cash Flow Statement

Operating Cash Flow (ttm) -173711008 USD
Levered Free Cash Flow (ttm) -139939744 USD

Profile of Coherus Oncology

Country United States
State CA
City Redwood City
Address 333 Twin Dolphin Drive
ZIP 94065
Phone 650 649 3530
Website https://www.coherus.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 145

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Q&A For Coherus Oncology Stock

What is a current CHRS stock price?

Coherus Oncology CHRS stock price today per share is 0.37 USD.

How to purchase Coherus Oncology stock?

You can buy CHRS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Coherus Oncology?

The stock symbol or ticker of Coherus Oncology is CHRS.

Which industry does the Coherus Oncology company belong to?

The Coherus Oncology industry is Biotechnology.

How many shares does Coherus Oncology have in circulation?

The max supply of Coherus Oncology shares is 154.54M.

What is Coherus Oncology Price to Earnings Ratio (PE Ratio)?

Coherus Oncology PE Ratio is now.

What was Coherus Oncology earnings per share over the trailing 12 months (TTM)?

Coherus Oncology EPS is -1.12 USD over the trailing 12 months.

Which sector does the Coherus Oncology company belong to?

The Coherus Oncology sector is Healthcare.

Coherus Oncology CHRS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Biotechnology Total Retu XNBI US 7414.87 USD —
-1.68
— — 7398.95 USD — 7631.86 USD — — — —
us US Tech Global Market Composite NQGM US 1743.91 USD —
-3.66
— — 1738.23 USD — 1808.43 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Composite Total Return XCMP US 27958.09 USD —
-5.28
— — 27828.65 USD — 29466.09 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.06T
Total marketcap
$150.05B
Total volume
BTC 57.62%   •   ETH 9.92%
Dominance
Select currency